Turkova, Anna; Wills, Genevieve H; Wobudeya, Eric; Chabala, Chishala; Palmer, Megan; Kinikar, Aarti; Hissar, Syed; ... Crook, Angela M; + view all Turkova, Anna; Wills, Genevieve H; Wobudeya, Eric; Chabala, Chishala; Palmer, Megan; Kinikar, Aarti; Hissar, Syed; Choo, Louise; Musoke, Philippa; Mulenga, Veronica; Mave, Vidya; Joseph, Bency; LeBeau, Kristen; Thomason, Margaret J; Mboizi, Robert B; Kapasa, Monica; van der Zalm, Marieke M; Raichur, Priyanka; Bhavani, Perumal K; McIlleron, Helen; Demers, Anne-Marie; Aarnoutse, Rob; Love-Koh, James; Seddon, James A; Welch, Steven B; Graham, Stephen M; Hesseling, Anneke C; Gibb, Diana M; Crook, Angela M; - view fewer (2022) Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. New England Journal of Medicine , 386 (10) pp. 911-922. 10.1056/nejmoa2104535.

Preview

Text Turkova_SHINE paper_NEJM_2022.pdf - Published Version Download (570kB) | Preview

Abstract

BACKGROUND: Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen. METHODS: We conducted an open-label, treatment-shortening, noninferiority trial involving children with nonsevere, symptomatic, presumably drug-susceptible, smear-negative tuberculosis in Uganda, Zambia, South Africa, and India. Children younger than 16 years of age were randomly assigned to 4 months (16 weeks) or 6 months (24 weeks) of standard first-line antituberculosis treatment with pediatric fixed-dose combinations as recommended by the World Health Organization. The primary efficacy outcome was unfavorable status (composite of treatment failure [extension, change, or restart of treatment or tuberculosis recurrence], loss to follow-up during treatment, or death) by 72 weeks, with the exclusion of participants who did not complete 4 months of treatment (modified intention-to-treat population). A noninferiority margin of 6 percentage points was used. The primary safety outcome was an adverse event of grade 3 or higher during treatment and up to 30 days after treatment. RESULTS: From July 2016 through July 2018, a total of 1204 children underwent randomization (602 in each group). The median age of the participants was 3.5 years (range, 2 months to 15 years), 52% were male, 11% had human immunodeficiency virus infection, and 14% had bacteriologically confirmed tuberculosis. Retention by 72 weeks was 95%, and adherence to the assigned treatment was 94%. A total of 16 participants (3%) in the 4-month group had a primary-outcome event, as compared with 18 (3%) in the 6-month group (adjusted difference, −0.4 percentage points; 95% confidence interval, −2.2 to 1.5). The noninferiority of 4 months of treatment was consistent across the intention-to-treat, per-protocol, and key secondary analyses, including when the analysis was restricted to the 958 participants (80%) independently adjudicated to have tuberculosis at baseline. A total of 95 participants (8%) had an adverse event of grade 3 or higher, including 15 adverse drug reactions (11 hepatic events, all but 2 of which occurred within the first 8 weeks, when the treatments were the same in the two groups). CONCLUSIONS: Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis. (Funded by the U.K. Medical Research Council and others; SHINE ISRCTN number, ISRCTN63579542. opens in new tab.)

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item